

**Sesterterpenes as TTL Inhibitors. First Insight of Structure-Activity Relationships and
Discovery of New Lead.**

Fabrizio Dal Piaz, Antonio Vassallo, Laura Lepore, Alessandra Tosco, Ammar Bader, Nunziatina De Tommasi.

Table of Contents


SI1. Stereochemistry of Compound 1.....	S2
SI2. Stereochemistry of Compound 2.....	S2
SI3. Extraction and isolation.....	S3
SI4. LC/MSⁿ analysis of crude acetone extract of <i>S. dominica</i>.....	S4
SI5. Cytotoxicity of Compound 11.....	S5

SI1. Stereochemistry of Compound 1

Due to the anisotropic effect of the benzene ring, negative $\Delta\delta(=\delta(-)-\delta(+))$ values were obtained for the signals ascribable to protons attached to the carbons at C-18 (-0.05) and C-20 (-0.03) of (+)-MTPA and (-)-MTPA esters of compound **1a**, while positive $\Delta\delta$ values were obtained for the signals due to the protons at C-15 (+0.04, +0.03 respectively), C-14 (+0.09), and C-21 (+0.03).

Compound 1a: Colorless amorphous powder. ESIMS m/z 439 $[M+Na]^+$, $C_{27}H_{44}O_3$. 1H NMR data (CD_3OD , 600 MHz) δ 1.30 (2H, m, H-11), 1.35 (3H, s, Me at C-19), 1.39 (3H, s, Me at C-19), 1.70 (3H, br s, Me-21), 1.78 (3H, br s, Me-20), 1.99 (1H, ddd, $J = 12.4, 4.5, 5.5$ Hz, H-12b), 2.02 (1H, ddd, $J = 12.4, 11.0, 4.5$ Hz, H-12a), 2.28 (1H, ddd, $J = 13.0, 5.5, 3.0$ Hz, H-12a), 2.52 (1H, ddd, $J = 13.0, 7.5, 3.0$ Hz, H-12a), 4.00 (

Scheme 1^a



^aReagents and conditions: (a) methyl lithium, diethyl ether, 0°C; (b) (+)- (MTPA) or (-)- (MTPA), DCC, DMAP, 25°C.


SI2. Stereochemistry of Compound 2

Comparison of relevant 1H NMR chemical shift differences between the *R*- and *S*-MTPA esters [H-14a (-0.05), H-14b (-0.03), H-13 (-0.02), H-21 (-0.02), H-18a (+0.07), H-18b (+0.05), H-16 (+0.05), H-17 (+0.02)] showed that the 1H NMR signals associate with the lactone ring system in the (*R*)-MTPA ester were shifted upfield relative to those of the (*S*)-MTPA, and the opposite was true for the resonances of the H-13, H-14, H-21. This is a proof for the C-15 (*S*)-configuration of **2**.

Compound 2a: Colorless amorphous powder. ESIMS m/z 445 $[M+Na]^+$, $C_{25}H_{42}O_5$. 1H NMR data

(CD₃OD, 600 MHz) δ 0.98 (3H, d, $J=6.5$ Hz, Me-20), 1.00 (3H, d, $J=6.0$ Hz, Me-21), 1.38 (1H, m, H-12a), 1.40 (2H, m, H-14), 1.43 (1H, m, H-12b), 1.65 (1H, m, H-13), 2.28 (1H, dd, $J=10.0, 5.5$ Hz, H-18), 2.56 (1H, m, H-17), 2.70 (1H, dd, $J=10.0, 7.0$ Hz, H-18), 3.91 (1H, dd, $J=8.0, 4.0$ Hz, H-15), 4.36 (1H, br t, $J=8.2$ Hz, H-16).

Scheme 2^a



^aReagents and conditions: (a) H₂/Pd, EtOH; (b) (+)- (MTPA) or (-)- (MTPA), DCC, DMAP, 25°C; (c) KOH 60°C, CH₂N₂, Et₂O 0°C; (d) 2,2-dimethoxypropane, THF, p-TsOH 25°C


S13. Extraction and isolation

The dried aerial parts of *S. dominica* (180 g) were powdered and exhaustively extracted using hexane (3.8 g), chloroform (7.2 g), chloroform-methanol (3.5 g), methanol (6 g), by ASE 2000. Part of CHCl₃-MeOH residue (3.0 g) was submitted to chromatographic separation on a Sephadex LH-20 column, using MeOH as mobile phase; fractions were collected, analysed by TLC on silica 60 F₂₅₄ gel-coated glass sheets with and CHCl₃-MeOH-H₂O (40:9:1), CHCl₃-MeOH (9:1), and grouped to obtain eight fractions (1-8). Fraction 3 (420 mg) was purified by preliminary SPE followed by RP-HPLC with MeOH-H₂O (67:33) as mobile phase (flow rate 2.0 ml min⁻¹) to afford pure compounds **2** (21.0 mg, $t_R = 20$ min), **3** (4.0 mg, $t_R = 21$ min), **5** (5.0 mg, $t_R = 33$ min), **6** (10.0 mg, $t_R = 45$ min), **7** (30 mg, $t_R = 12$ min), **8** (9 mg, $t_R = 26$ min), **13** (24.0 mg, $t_R = 8$ min), **14** (6.0 mg, $t_R = 16$ min). Fraction 4 (72 mg) was chromatographed over RP-HPLC with MeOH-H₂O (67:33) as mobile phase (flow rate 2.0 ml min⁻¹) to yield pure compounds **2** (19 mg, $t_R = 20$ min), **3** (2.5 mg, $t_R = 21$ min), **4** (3.5 mg, $t_R = 24$ min), **7** (13.0 mg, $t_R = 12$ min), **8** (3.0 mg, $t_R = 26$ min), and **13** (8.0 mg, $t_R = 8$ min). Fraction 5 (60 mg) was subjected to RP-HPLC with MeOH-H₂O (3:2)

as eluent (flow rate 2.0 ml min⁻¹) to yield pure compounds **3** (4.0 mg, t_R = 20 min), **4** (2.0 mg, t_R = 33 min), and **10** (15 mg, t_R = 22 min). Fraction 7 contained pure rosmarinic acid (12 mg). Part of chloroform extract (6.0 g) was subjected to column chromatography using silica gel and eluting with CHCl₃ followed by increasing concentrations of MeOH in CHCl₃ (between 1% and 70%). Fractions of 50 ml were collected, analysed by TLC (silica gel plates, in CHCl₃ or mixtures CHCl₃-MeOH 99:1, 98:2, 97:3, 9:1, 4:1; CHCl₃-MeOH-H₂O 40:9:1), and grouped into 20 fractions (A-V). Fraction V contained pure rosmarinic acid (7 mg). Fraction F (40 mg) was subjected to RP-HPLC with MeOH-H₂O (33:22) as eluent (flow rate 2.0 ml min⁻¹) to give pure compounds **3** (3.0 mg, t_R = 19 min), and **5** (6 mg, t_R = 30 min). Fraction G (45 mg) was subjected to RP-HPLC with MeOH-H₂O (7:3) as mobile phase (flow rate 2.0 ml min⁻¹) to yield compounds **3** (15.0 mg, t_R = 12 min), **4** (11.0 mg, t_R = 23 min), **5** (8.0 mg, t_R = 35 min), and **11** (3.0 mg, t_R = 52 min). Fraction H (95 mg) was purified by RP-HPLC using MeOH-H₂O (34:16) as mobile phase (flow rate 2.0 ml min⁻¹) to give compounds **3** (3.0 mg, t_R = 20 min), **4** (5.0 mg, t_R = 20 min), **6** (3.0 mg, t_R = 36 min). Fraction M (99 mg) was subjected to RP-HPLC with MeOH-H₂O (3:2) as eluent (flow rate 2.0 ml min⁻¹) to give pure compounds **1** (9.0 mg, t_R = 45 min), **8** (10.0 mg, t_R = 30 min), **9** (3.5 mg, t_R = 27 min), **12** (6.5 mg, t_R = 18 min), **13** (15.0 mg, t_R = 25 min). Fraction O (99 mg) was purified by preliminary SPE followed by RP-HPLC with MeOH-H₂O (3:2) (flow rate 2.0 ml min⁻¹) to give pure compounds **1** (22.0 mg, t_R = 45 min), **2** (16.0 mg, t_R = 42 min), **13** (3.0 mg, t_R = 25 min), **16** (4.0 mg, t_R = 32 min), **18** (18.5 mg, t_R = 68 min). Fraction P (214 mg) was subjected to RP-HPLC using MeOH-H₂O (58:42) (flow rate 2.0 ml min⁻¹) to give pure compounds **2** (14.0 mg, t_R = 45 min), **10** (2.0 mg, t_R = 23 min), **13** (9.0 mg, t_R = 27 min), **17** (10.0 mg, t_R = 21 min), **19** (15.0 mg, t_R = 27 min), **20** (12.0 mg, t_R = 35 min), **21** (16.0 mg, t_R = 32 min), and **22** (10.0 mg, t_R = 18 min). Fraction Q (312 mg) was subjected to RP-HPLC with MeOH-H₂O (58:42) as mobile phase (flow rate 2.0 ml min⁻¹) to give pure compounds **7** (35.0 mg, t_R = 33 min), **10** (3.0 mg, t_R = 22 min), and **13** (4.0 mg, t_R = 28 min). Fraction R (250 mg) was subjected to RP-HPLC with MeOH-H₂O (58:42) (flow rate 2.0 ml min⁻¹) to give pure compounds **7** (22.0 mg, t_R = 34 min), **9** (4.0 mg, t_R = 38 min), **10** (4.0 mg, t_R = 23 min), **13** (3.0 mg, t_R = 27 min), **15** (4.0 mg, t_R = 52 min). Fraction S (72 mg) was subjected to RP-HPLC using MeOH-H₂O (55:45) as mobile phase (flow rate 2.0 ml min⁻¹) to give pure compounds **7** (15.0 mg, t_R = 53 min), **13** (3.0 mg, t_R = 40 min), **22** (9 mg, t_R = 24 min). Fraction T (110 mg) was subjected to RP-HPLC using MeOH-H₂O (55:45) as eluent (flow rate 2.0 ml min⁻¹) to give pure compounds **7** (4.0 mg, t_R = 53 min), **23** (14 mg, t_R = 24 min), **24** (11 mg, t_R = 47 min).

SI4. LC/MSⁿ analysis of crude acetone extract of *S. dominica*

To confirm the co-presence of compounds **13** and **4**, and **19** and **20**, the crude acetone extract of *S. dominica* underwent LC/MSⁿ analysis. MS and MS/MS spectra of peaks at 27.2 min, 28.6 min, 34.0 min and 35.1 min allowed us to identify them as compounds **13**, **4**, **19** and **20**, respectively. LC/MSⁿ analysis was performed in positive ion mode on a ThermoFinnigan LCQ Deca XP Max ion-trap mass spectrometer equipped with Xcalibur software. Chromatographic separation was achieved using a Luna C₁₈ (150x2 mm, Phenomenex, USA) column and 0.1% TFA in H₂O (solvent A) and 0.1% TFA in CH₃CN (solvent B) mobile phase. A 50 min linear gradient from 35 to 85 % of solvent B was used.



LC/MSⁿ analysis of acetone crude extract of *S. dominica*: Total ion current chromatogram (A). MS² spectra of ion at m/z 457 detected at 27.2 min (B). MS² spectra of ion at m/z 457 detected at 28.6 min (C).

SI5. Cytotoxicity of Compound 11

